Skip to main content
main-content

01.06.2015 | Original Article | Ausgabe 6/2015

Supportive Care in Cancer 6/2015

Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer

Zeitschrift:
Supportive Care in Cancer > Ausgabe 6/2015
Autoren:
Madoka Kimura, Tateaki Naito, Hirotsugu Kenmotsu, Tetsuhiko Taira, Kazushige Wakuda, Takuya Oyakawa, Yasushi Hisamatsu, Takaaki Tokito, Hisao Imai, Hiroaki Akamatsu, Akira Ono, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Keita Mori, Toshiaki Takahashi, Nobuyuki Yamamoto
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00520-014-2534-3) contains supplementary material, which is available to authorized users.

Abstract

Purpose

Cancer cachexia (CC) is commonly seen in advanced lung cancer patients and associated with poor prognosis. However, little is known about CC that develops during chemotherapy. We evaluated the prognostic impact of CC and skeletal muscle wasting that develops during the course of chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.

Methods

The clinical data of 134 newly diagnosed NSCLC patients were retrospectively reviewed. CC was defined as a body weight loss >5 or >2 % in patients with a body mass index of <20 kg/m2. CC was assessed at baseline (T1) and 3 months (T2), 6 months (T3), and 12 months (T4) after chemotherapy initiation. Skeletal muscle mass was assessed using the lumber skeletal muscle index (LSMI).

Results

The proportion of patients with CC at T1, T2, T3, and T4 was 45.6, 46.1, 25.5, and 26.0 %, respectively. The frequency of grade 3 chemotherapy-induced anorexia was higher in patients with CC than those without CC at T2 (15.4 vs. 0.0 %, P = 0.0044). At all time points, patients with CC had shorter survival times than those without CC. Patients with low LSMIs (men, <41 cm2/m2; women, <38 cm2/m2) tended to have poor prognosis. Adjusted Cox proportional hazard ratios and corresponding confidence intervals for CC at T1, T2, T3, and T4 were 2.53 (1.33–4.88), 1.97 (1.27–3.06), 3.86 (2.14–6.81), and 1.62 (0.80–3.16), respectively.

Conclusion

CC presence and decreased skeletal muscle mass are associated with poor prognosis in advanced NSCLC patients receiving chemotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Table S1 (DOCX 15 kb)
520_2014_2534_MOESM1_ESM.docx
Table S2 (DOCX 15 kb)
520_2014_2534_MOESM2_ESM.docx
Table S3 (DOCX 16 kb)
520_2014_2534_MOESM3_ESM.docx
Table S4 (DOCX 16 kb)
520_2014_2534_MOESM4_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2015

Supportive Care in Cancer 6/2015 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise